摘要
2006年6月美国FDA批准了第一个用于预防宫颈癌的疫苗,即可以预防人乳头瘤病毒(human papillomavirus。HPV)6、11、16和18型感染的四价疫苗,70%的宫颈癌和90%的生殖器疣由这些型别引起。还有一种可以预防HPV16和18型的二价HPV疫苗也已上市。此文主要就治疗性和预防性HPV疫苗的发展情况做一综述。
The US Food and Drug Administration licensed the first vaccine to prevent cervical cancers in women in June 2006. The quadrivalent vaccine protects against human papillomavirus (HPV)-6, -11, -16, and -18, which are responsible for 70% of cervical cancers and 90% of genital warts. The second is a bivalent vaccine preventing from infection of two high-risk oncogenic HPV types (16 and 18 ). This article reviews the biology of HPV that allows for the development of both therapeutic and prophylactic vaccines.
出处
《国际生物制品学杂志》
CAS
2009年第2期83-86,共4页
International Journal of Biologicals